Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 26;28(3):1988-2006.
doi: 10.3390/curroncol28030185.

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019

Joanna Gotfrit  1 , Rachel Goodwin  1 , Timothy Asmis  1 , Angela J Hyde  1 , Thierry Alcindor  2 , Francine Aubin  3 , Scott Berry  4 , Dominick Bossé  1 , Colin Brown  5 , Ronald Burkes  6 , Margot Burnell  7 , Bruce Colwell  8 , Jessica Corbett  5 , Jeff Craswell  9 , Nathalie Daaboul  10 , Mark Doherty  11 , D A Barry Fleming  12 , Luisa Galvis  13 , Rakesh Goel  1 , Mohammed Harb  14 , Alwin Jeyakumar  8 , Derek Jonker  1 , Erin Kennedy  6 , Michael Lock  15 , Aamer Mahmud  4 , Patrick H McCrea  5   8 , Vimoj Nair  1 , Rami Nassabein  3 , Carolyn Nessim  1 , Ravi Ramjeesingh  8 , Muhammad Raza  13 , Wissam Saliba  16 , Satareh Samimi  17 , Simron Singh  11 , Stephanie Snow  8 , Mustapha Tehfé  3 , Michael Thirlwell  2 , Mario Valdes  18 , Stephen Welch  15 , Michael Vickers  1
Affiliations

Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019

Joanna Gotfrit et al. Curr Oncol. .

Abstract

The annual Eastern Canadian Gastrointestinal Cancer Consensus Conference 2019 was held in Morell, Prince Edward Island, 19-21 September 2019. Experts in medical oncology, radiation oncology, and surgical oncology who are involved in the management of patients with gastrointestinal malignancies participated in presentations and discussion sessions for the purpose of developing the recommendations presented here. This consensus statement addresses multiple topics in the management of anal, colorectal, biliary tract, and gastric cancers, including: radiotherapy and systemic therapy for localized and advanced anal cancer; watch and wait strategy for the management of rectal cancer; role of testing for dihydropyrimidine dehydrogenase (DPD) deficiency prior to commencement of fluoropyrimidine therapy; radiotherapy and systemic therapy in the adjuvant and unresectable settings for biliary tract cancer; and radiotherapy and systemic therapy in the perioperative setting for early-stage gastric cancer.

Keywords: anal cancer; biliary tract cancer; chemotherapy; colon cancer; gastric cancer; guidelines; radiation therapy; rectal cancer; surgery.

PubMed Disclaimer

Conflict of interest statement

Thierry Alcindor has been a consultant for Amgen, Bayer, BMS, Eisai, Lilly, Merck, Novartis Canada Pharmaceuticals, Pfizer, EMD Serono, Roche, Taiho, and AstraZeneca. Francine Aubin has received honoraria from Taiho Pharma, and Merck, and has received institutional research grants from Bristol Myers Squibb, and Merck, and has participated at scientific advisory boards with Taiho Pharma, Amgen, Bristol Myers Squibb, Pfizer, and Merck. Dominick Bossé has received honoraria (speaker/consultancy) from Amgen, Ipsen, Merck, BMS, AsraZeneka, Bayer, Abbvie, and Janssen. Ronald Burkes has received honoraria from Merck, Bristol Myers Squibb, Pfizer, Amgen, and AstraZeneca. Bruce Colwell has been a speaker and member of advisory boards for Amgen, Celgene, Novartis, Merck, Apobiologix, Roche, Shire, and Canadian Society of Internal Medicine. Mark Doherty has received honoraria from Roche, AstraZeneca, Boehringer Ingelheim, Merck, and has received research funding from Merck, AstraZeneca, Eisai, and Boehringer Ingelheim. Luisa Galvis has been a member of advisory boards for Ipsen, Roche, Pfizer, AstraZeneca, AAA/Novartis, and EMD Serono Rachel Goodwin has been a speaker/consultant for Merck, Pfizer, Bayer, Ipsen, Novartis (AAA), Eisai, Amgen, Apobiologix, and has received independent research grants from Apobiologix, Ipsen, and Novartis. Muhammad Raza has been a member of advisory boards from Jensen, Roche, Merck, and Pfizer. Ravi Ramjeesingh has received honoraria from Amgen, BMS, Bayer, Celgene, Ipsen, Eisai, Merck, Novartis, Servier, and Knight Pharmaceutical. Wissam Saliba has received honoraria from Ipsen, Pfizer, AstraZeneca, Bayer, Genomic Health, and Celgene. Simron Singh has received institutional research funding from AAA/Novartis, EMD Serono, and has participated in an advisory board for IPSEN. Stephanie Snow has participated in advisory boards for Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, EMD Serono, Eisai, Merck, Novartis, Pfizer, Roche, Taiho, and Takeda, and has received research funding/trial involvement from AstraZeneca, Bristol Myers Squibb, EMD Serono, Merck, Novartis, and Takeda, and has received speaker honoraria from Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Merck, PeerVoice, and Taiho. Mustapha Tehfé has done advisory boards with Pfizer, Takeda, Taiho, Bristol Myers Squibb, and MERCK, and has received honoraria from Pfizer, Taiho, Merck, and Bristol Myers Squib. Michael Vickers has received honoraria from Merck and Amgen. Stephen Welch has done advisory boards with Merck and Pfizer. The other authors declare no conflict of interest.

References

    1. Statistics Canada . Canadian Cancer Registry. Statistics Canada; Ottawa, ON, Canada: 2020.
    1. Touboul E., Schlienger M., Buffat L., Lefkopoulos D., Pène F., Parc R., Tiret E., Gallot D., Malafosse M., Laugier A. Epidermoid carcinoma of the anal canal. Results of curative-intent radiation therapy in a series of 270 patients. Cancer. 1994;73:1569–1579. doi: 10.1002/1097-0142(19940315)73:6<1569::AID-CNCR2820730607>3.0.CO;2-F. - DOI - PubMed
    1. Nigro N.D., Vaitkevicius V.K., Considine B., Jr. Combined therapy for cancer of the anal canal: A preliminary report. Dis. Colon Rectum. 1974;17:354–356. doi: 10.1007/BF02586980. - DOI - PubMed
    1. Bartelink H., Roelofsen F., Eschwege F., Rougier P., Bosset J.F., Gonzalez D.G., Peiffert D., Van Glabbeke M., Pierart M. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J. Clin. Oncol. 1997;15:2040–2049. doi: 10.1200/jco.1997.15.5.2040. - DOI - PubMed
    1. Northover J., Glynne-Jones R., Sebag-Montefiore D., James R., Meadows H., Wan S., Jitlal M., Ledermann J. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I) Br. J. Cancer. 2010;102:1123–1128. doi: 10.1038/sj.bjc.6605605. - DOI - PMC - PubMed

Publication types

LinkOut - more resources